PMID- 24711443
OWN - NLM
STAT- MEDLINE
DCOM- 20140812
LR  - 20220317
IS  - 1934-6638 (Electronic)
IS  - 1934-662X (Linking)
VI  - 122
IP  - 6
DP  - 2014 Jun
TI  - Usefulness of GATA3 and p40 immunostains in the diagnosis of metastatic 
      urothelial carcinoma in cytology specimens.
PG  - 468-73
LID - 10.1002/cncy.21424 [doi]
AB  - BACKGROUND: GATA3 (GATA-binding protein 3) expression in urothelial carcinoma 
      (UC) and mammary carcinomas has been recently reported. However, to the authors' 
      knowledge, studies examining GATA3 staining of metastatic UC (MUC) in cytology 
      specimens are lacking. Delta Np63 (p40) has been shown to be expressed highly 
      selectively in squamous cell carcinomas (SCCs) but the literature concerning the 
      expression of p40 in UC is limited and controversial. In the current study, the 
      authors evaluated the usefulness of GATA3 and p40 in the diagnosis of MUC in 
      cytology specimens. METHODS: Thirty-two MUC cytology cases and 44 controls (22 UC 
      cases and 22 SCC cases) were stained for GATA3, p40, and p63 and nuclear staining 
      intensity and the percentage of positive cells were recorded and compared. 
      RESULTS: MUC cytology cases stained positive for GATA3, p40, and p63 in 78.13%, 
      80.65%, and 61.29% of cases, respectively, with moderate/strong staining 
      intensity. MUC cases had a significantly higher percentage of GATA3 positivity 
      compared with SCC controls (P<.001), but GATA3 positivity was not found to be 
      significantly different from UC controls (90.91%) (P = .28). For p40 positivity, 
      there was no significant difference observed between MUC cases, UC controls 
      (95.45%), and SCC controls (90.91%) (P=.29). p63 positivity was found to be 
      significantly lower in MUC cases compared with UC controls (95.45%) and SCC 
      controls (95.45%) (P<.01). CONCLUSIONS: The results of the current study 
      demonstrate that GATA3 is useful in confirming the diagnosis of MUC in cytology 
      specimens and in distinguishing between MUC and SCC. p40 is a valuable adjunct to 
      GATA3 in the diagnosis of MUC in cytology specimens, especially when SCC is not 
      part of the clinical differential diagnosis.
CI  - (c) 2014 American Cancer Society.
FAU - Brandler, Tamar C
AU  - Brandler TC
AD  - Department of Pathology, Hofstra North Shore-LIJ School of Medicine, Lake 
      Success, New York.
FAU - Aziz, Mohamed S
AU  - Aziz MS
FAU - Rosen, Lisa M
AU  - Rosen LM
FAU - Bhuiya, Tawfiqul A
AU  - Bhuiya TA
FAU - Yaskiv, Oksana
AU  - Yaskiv O
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140407
PL  - United States
TA  - Cancer Cytopathol
JT  - Cancer cytopathology
JID - 101499453
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (GATA3 Transcription Factor)
RN  - 0 (GATA3 protein, human)
RN  - 0 (Immunodominant Epitopes)
RN  - 0 (P40, iodinated C-terminal peptide, human)
RN  - 0 (Peptide Fragments)
RN  - 0 (Protein Isoforms)
RN  - 0 (TP63 protein, human)
RN  - 0 (Transcription Factors)
RN  - 0 (Tumor Suppressor Proteins)
SB  - IM
MH  - Biomarkers, Tumor/immunology/*metabolism
MH  - Carcinoma, Squamous Cell/*diagnosis/metabolism
MH  - Case-Control Studies
MH  - Cytodiagnosis/methods
MH  - Follow-Up Studies
MH  - GATA3 Transcription Factor/immunology/*metabolism
MH  - Humans
MH  - Immunodominant Epitopes/immunology/*metabolism
MH  - Immunoenzyme Techniques
MH  - Logistic Models
MH  - Peptide Fragments/immunology/*metabolism
MH  - Prognosis
MH  - Protein Isoforms
MH  - Sensitivity and Specificity
MH  - Transcription Factors/immunology/*metabolism
MH  - Tumor Suppressor Proteins/immunology/*metabolism
MH  - Urologic Neoplasms/*diagnosis/metabolism
OTO - NOTNLM
OT  - GATA3 (GATA-binding protein 3)
OT  - cytology
OT  - immunocytochemistry
OT  - p40
OT  - urothelial carcinoma
EDAT- 2014/04/09 06:00
MHDA- 2014/08/13 06:00
CRDT- 2014/04/09 06:00
PHST- 2014/02/11 00:00 [received]
PHST- 2014/03/11 00:00 [revised]
PHST- 2013/03/12 00:00 [accepted]
PHST- 2014/04/09 06:00 [entrez]
PHST- 2014/04/09 06:00 [pubmed]
PHST- 2014/08/13 06:00 [medline]
AID - 10.1002/cncy.21424 [doi]
PST - ppublish
SO  - Cancer Cytopathol. 2014 Jun;122(6):468-73. doi: 10.1002/cncy.21424. Epub 2014 Apr 
      7.